

1 Carriage of antimicrobial-resistant Enterobacterales among pregnant 2 women and newborns in Amhara, Ethiopia

3
4 Getnet Amsalu^{a,b1}; Christine Tedijanto Wen^{c1}, PhD; Olga Perovic^{d,e}, MD, DTM&H, MMED
5 (WITS), FCPATH (SA); Addisalem Gebru^{b,f}; Bezawit M. Hunegnaw^{a,b,g}, MD, MPH; Fisseha
6 Tadesse^f, MD; Marshagne Smith^e; Addisalem Fikre^{a,b}, MPH; Delayehu Bekele^{a,b,h,j}, MD, MPH;
7 Lisanu Tadesse^b, MD, MPH; Grace Chan^{a,b,i,j*}, MD, MPH, PhD

8
9 ^aSt. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia

10 ^bHaSET Maternal and Child Health Research Program

11 ^cSurgo Health, District of Columbia, USA

12 ^dThe National Institute for Communicable Diseases, a division of NHLS, Johannesburg, South
13 Africa

14 ^eUniversity of Witwatersrand, Department of Clinical Microbiology and Infectious Diseases,
15 Johannesburg, South Africa

16 ^fDebre Birhan Hospital, Debre Birhan, Ethiopia

17 ^gDepartment of Pediatrics and Child Health, St. Paul's Hospital Millennium Medical College,
18 Addis Ababa, Ethiopia

19 ^hDepartment of Obstetrics and Gynecology, St. Paul's Hospital Millennium Medical College,
20 Addis Ababa, Ethiopia

21 ⁱDivision of Medical Critical Care, Boston Children's Hospital, Harvard Medical School, Boston,
22 MA, USA

23 ^jDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

24
25 ¹These authors contributed equally to the manuscript.

26 27 *Corresponding author:

28 Grace Chan

29 Harvard T.H. Chan School of Public Health

30 677 Huntington Avenue, Kresge 913, Boston, MA 02115

31 1-617-432-3422

32 grace.chan@hsph.harvard.edu

33
34 **Keywords:** antibiotic resistance, ESBL, CRE, neonates, pregnancy, sepsis, vertical
35 transmission

36
37 **Main point:** Carriage prevalence of ESBL-producing Enterobacterales was high among
38 pregnant women and neonates in a rural area of Ethiopia, and neonates were more likely to test
39 positive if their mother tested positive. This work informs prevention and treatment of neonatal
40 infections.

41 **Abstract**

42

43 *Background*

44

45 Infections are one of the most common causes of neonatal mortality, and maternal colonization
46 has been associated with neonatal infection. Data on carriage of bacterial pathogens and
47 mother-child transmission patterns in low- and middle-income countries is sparse.

48

49 *Methods*

50

51 We sought to quantify carriage prevalence of extended-spectrum-beta-lactamase (ESBL) -
52 producing and carbapenem-resistant Enterobacterales (CRE) among pregnant women and their
53 neonates and to characterize risk factors for carriage in a rural area of Amhara, Ethiopia. We
54 sampled 211 pregnant women in their third trimester and/or labor/delivery and 159 of their
55 neonates in the first week of life.

56

57 *Results*

58

59 We found that carriage of ESBL-producing organisms was fairly common (women: 22.3%, 95%
60 CI: 16.8-28.5; neonates: 24.5%, 95% CI: 18.1-32.0), while carriage of CRE (women: 0.9%, 95%
61 CI: 0.1-3.4; neonates: 2.5%, 95% CI: 0.7-6.3) was rare. Neonates whose mothers tested
62 positive for ESBL-producing organisms were nearly twice as likely to also test positive for ESBL-
63 producing organisms (38.7% vs. 21.1%, p-value: 0.06). Carriage of ESBL-producing organisms
64 was also associated with woreda (district) of sample collection (Fisher exact test maternal p-
65 value: <0.01; neonatal p-value: <0.01) and recent antibiotic use (maternal p-value: 0.55;
66 neonatal p-value: 0.011).

67

68 *Conclusions*

69

70 Understanding carriage patterns of potential pathogens and antibiotic susceptibility among
71 pregnant women and newborns in this region will help to inform local, data-driven
72 recommendations to prevent and treat neonatal infections.

73 Introduction

74
75 Neonatal infections, particularly sepsis, meningitis, and pneumonia, are among the most
76 common causes of mortality in the first 28 days of life, accounting for approximately 23% of 2.4
77 million neonatal deaths worldwide [1,2]. Treatment of infections is increasingly challenging in the
78 context of antimicrobial resistance, with over 40% of neonatal sepsis cases estimated to have
79 resistance or reduced susceptibility to both the first- (ampicillin/penicillin and gentamicin) and
80 second-line (third-generation cephalosporins) treatments recommended by the World Health
81 Organization (WHO) [3]. Better understanding of the pathways leading to neonatal infection
82 could inform critical infection prevention strategies.

83
84 Maternal colonization has been shown to be associated with neonatal infection [4]. Shared
85 pathogens between mothers and their newborns may be a result of vertical transmission at birth
86 and/or common environmental exposures. This phenomenon has been well-studied in high-
87 income settings, particularly for *Streptococcus agalactiae*/Group B *Streptococcus* (GBS), once a
88 leading cause of neonatal infections in the United States. Resulting interventions such as
89 prenatal screening and antibiotic prophylaxis during labor have decreased the incidence of
90 invasive early-onset GBS disease by over 80% [5,6].

91
92 However, relatively little is known about maternal colonization and subsequent neonatal
93 infections in low- and middle-income settings. Unfortunately, this often overlaps with settings
94 with high burden of disease; for example, Sub-Saharan Africa has the highest levels of neonatal
95 mortality at 27 deaths per 1000 live births (accounting for 43% of global newborn deaths) [2],
96 and infections have been found to contribute a greater proportion of deaths in high neonatal
97 mortality settings [7]. Data specific to these populations is greatly needed to inform relevant
98 clinical guidelines.

99
100 Our study focused on pregnant women and newborns in the Birhan field site, a surveillance site
101 focused on maternal and child health in North Shewa Zone, Amhara, Ethiopia [8]. In this cohort
102 between November 2018 and December 2020, overall neonatal mortality was 3.1% of live births
103 [9]. We estimated carriage prevalence of Gram-negative antibiotic-resistant organisms –
104 extended-spectrum-beta-lactamase (ESBL) -producing organisms and carbapenem-resistant
105 *Enterobacterales* (CRE). We also checked samples for the presence of GBS due to its global
106 importance in neonatal infections. Using samples collected at antenatal care (ANC),
107 labor/delivery, and during the first week of life, we assessed longitudinal carriage patterns
108 during pregnancy and between mothers and their newborns. In addition, we studied the
109 association between colonization with our organisms of interest and clinical and environmental
110 risk factors.

111
112 Ethical clearance for this study was obtained from the Ethics Review Board (IRB) of Saint Paul's
113 Hospital Millennium Medical college, (Addis Ababa, Ethiopia) [PM23/274], Boston Children's
114 Hospital (Boston, United States) [IRB-P00028224], and Harvard T.H. Chan School of Public
115 Health (Boston, United states) [IRB19-0991].

116

117 **Methods**

118

119 *Study setting*

120

121 We conducted a prospective cohort study at the Birhan field site, including 16 villages in
122 Amhara Region, Ethiopia with a total population of 77,766. The catchment area is rural and
123 semi-urban, covers both highland and lowland areas, and includes two different districts,
124 Angolela Tera, and Kewot/Shewa Robit. The site includes a health and demographic
125 surveillance system (HDSS), the Birhan HDSS, with house-to-house surveillance every three
126 months to estimate morbidity and mortality outcomes among 17,108 women of reproductive age
127 and 8,554 children under five years old. The site is a platform for community and facility-based
128 research and training that was established in 2018 [8]. Nested in the site is an open pregnancy
129 and birth cohort, the Birhan cohort, that enrolls approximately 2,000 pregnant women and their
130 newborns per year with rigorous longitudinal follow-up over the first two years of life and
131 household data linked with health facility information [10].

132

133 *Sample collection*

134

135 Samples were collected from March to August 2022. Any pregnant woman who had an address
136 in one of the Birhan catchment villages and visited any of the Birhan health facilities for an
137 antenatal care (ANC) visit at >35 weeks or for labor/delivery was considered for enrollment in
138 the study. Among women who were enrolled at ANC, follow-up samples at labor/delivery were
139 collected at any of the Birhan health facilities.

140

141 Signed informed consent was obtained from all participants upon enrollment in the study. After
142 receiving informed consent, the trained data collectors collected samples and administered the
143 study questionnaire in the facility. Samples were excluded if complications such as premature
144 rupture of membranes (PROM), antepartum hemorrhage, or genital ulcers were present. If a
145 woman contributed her first samples at ANC, follow-up samples were requested at
146 labor/delivery occurring in facilities. At each visit, Dacron swabs were used to collect two
147 samples from each woman, one rectal and one vaginal. Neonatal samples were collected at day
148 6 after birth, coinciding with an existing follow-up visit in the ongoing Birhan MCH cohort. Either
149 perirectal or stool samples were collected based on the family's preference. Families could
150 refuse to provide samples at any time.

151

152 Swabs were stored in facility refrigerators for up to 24 hours before being transported to Debre
153 Birhan Hospital, the referral hospital for the North Shewa Zone. At Debre Birhan Hospital,
154 samples were stored at 2-8°C for up to 3 weeks (typically <14 days) before shipment to the
155 National Institute for Communicable Diseases (NICD) in South Africa. Standardized sample
156 transportation techniques (e.g., triple packaging of samples) were used to maintain the viability
157 of organisms and safety of the public and environment.

158

159 *Sample processing - antimicrobial susceptibility testing*

160

161 Phenotypic identification and determination of antimicrobial susceptibility were performed at
162 NICD, a division of National Health Laboratory Service (NHLS), South Africa. Interpretation of
163 susceptibility breakpoints was according to Standard Clinical and Laboratory Standards Institute
164 (CLSI) guidelines [11].

165 Samples received at NICD were processed upon receipt in the laboratory. A worksheet was
166 created for each batch of processed swabs. Each swab was plated on following media: (1)
167 MacConkey agar with an imipenem disc placed on the initial inoculum as an additional screen
168 for carbapenem resistant organisms, (2) Colorex™ESBL for detection of Gram-negative
169 bacteria producing Extended Spectrum Beta-Lactamase (ESBL), (3)
170 Colorex™mSuperCARBA™ for detection and isolation of Carbapenem-Resistant
171 *Enterobacteriales* (CRE), and (4) Todd Hewitt enrichment broth for *Streptococcus agalactiae*
172 (GBS). Plates and broths were incubated for 24-hours at 37°C.

173 Colorex™ agar plates were examined for colonies demonstrating various color changes
174 according to the manufacturer's instructions for each of the Colorex™ media used. MacConkey
175 agar plates were examined for Gram negative bacteria growing close to the imipenem disc.
176 Suspected colonies on Colorex™ media were plated out on MacConkey agar for identification
177 and antimicrobial susceptibility testing. After 24-hours of incubation, colonies were identified
178 using the MALDI TOF-MS Biotyper® system (Bruker Daltonics GmbH, Bremen, Germany) and
179 AST performed on MicroScan® (Beckman Coulter, Inc., West Sacramento, CA, USA) using
180 Microscan® Neg MIC Panel Type 44. The Todd Hewitt enrichment broth was sub-cultured on a
181 blood agar plate and Colorex™StrepB agar plate and incubated for 24 hours at 37°C.

182 Suspected colonies from blood agar were identified on the MALDI Biotyper®. Suspected
183 colonies from Colorex™StrepB agar were plated out on blood agar prior to identification and
184 AST. Isolates of GBS underwent MIC testing using the Sensititre (ThermoFisher).
185 *Streptococcus* species STP6F Trek panel as well as Kirby Bauer disc susceptibility testing.
186 Isolates of ESBL-producing organisms, CRE and GBS, were stored in tryptic soy broth with 10%
187 glycerol in -70°C.

188 *Sample processing - molecular testing*

189 Molecular testing was also conducted to verify the presence of ESBL genes among isolates
190 identified as ESBL-positive by antimicrobial susceptibility testing profiles to the third and fourth
191 generation of cephalosporins identified by MicroScan®. The DNA was extracted using a crude
192 boiling method at 95°C for 25 minutes. The DNA templates were then tested for the presence of
193 extended-spectrum beta-lactamase (ESBL) genes such as *bla*_{-TEM}, *bla*_{-SHV} and *bla*_{-CTXM} using the
194 LightCycler 480 instrument (Roche Applied Science, Germany) and LightCycler 480 Probes
195 Master kit (Roche Diagnostics, USA) in a real-time polymerase chain reaction (PCR) assay. The
196 *bla*_{-TEM}, *bla*_{-SHV} and *bla*_{-CTXM} genes were amplified by multiplex real-time PCR using the primers
197 and probes shown in **Supplementary Table 1**. For *bla*_{-TEM} and *bla*_{-SHV}, the reaction conditions
198 were 10µM primers, 2µM probes, denaturation for 95°C for 5 minutes, and then 45 cycles of
199 95°C for 10 seconds, 55°C for 30 seconds and 72°C for 1 second. The *bla*_{-CTXM} PCR was a

200 multiplex assay targeting *bla*_{-CTXM} group M1 and M2-9 using primer and probe sequences as
201 described previously [12].

202

203 *Sample processing - whole genome sequencing*

204

205 Whole genome sequencing was conducted to verify the presence of CRE genes among isolates
206 identified as CRE-positive by antimicrobial susceptibility testing profiles to carbapenems
207 identified by MicroScan®. Genomic DNA (gDNA) was extracted using QIAamp DNA mini kit
208 (Qiagen, TX, USA) following the manufacturer's instructions. The concentrations of the
209 extracted gDNA were determined using Qubit 4.0 fluorometer (ThermoFisher Scientific,
210 Waltham, MA, USA). Multiplexed paired-end libraries were prepared using the Illumina DNA
211 Prep kit (Illumina, San Diego, CA, USA). Sequencing was performed on Illumina NextSeq 550
212 platform (Illumina, San Diego, CA, USA) (2x 150bp) with 100x coverage at the NICD
213 Sequencing Core Facility, NHLS, South Africa.

214

215 Raw paired-end reads were analysed using the Jekesa pipeline (v1.0;
216 <https://github.com/stanikae/jekesa>). Briefly, Trim Galore! (v0.6.2;
217 <https://github.com/FelixKrueger/TrimGalore>) was used to filter the generated sequence raw
218 reads (Q >30 and length >50 bp). De novo assembly and optimization of the contigs were
219 performed using SPAdes v3.13 and Shovill (v1.1.0; <https://github.com/tseemann/shovill>),
220 respectively. The multilocus sequence typing (MLST) profiles were determined using the MLST
221 tool (version 2.16.4; <https://github.com/tseemann/mlst>). Assembly metrics were calculated using
222 QUAST (v5.0.2; <http://quast.sourceforge.net/quast>).

223

224 Whole-genome single nucleotide polymorphism (SNP) differences were determined with a
225 reference-free approach using the SKA toolkit [13]. Antibiotic resistance profiles and virulence
226 genes were predicted using ABRicate (version 1.0.1; <https://github.com/tseemann/ABRicate>),
227 against the Comprehensive Antibiotic Resistance Database (CARD), ResFinder - Center for
228 Genomic Epidemiology (CGE) database [14], NCBI AMRFinderPlus [15], and Virulence Factor
229 Database (VFDB) [16] implemented in the Jekesa pipeline. Pathogen Watch
230 (<https://pathogen.watch/>) was used to construct the phylogenetic tree [Newick (NWK) file]. The
231 exported NWK file was used in Microreact (<https://microreact.org/showcase>) to visualize and
232 edit the phylogenetic tree. The assembled genome files were submitted to the National Center
233 for Biotechnology Information GenBank and are available under BioProject number:
234 PRJNA819852[RM1].

235 *Statistical analysis*

236

237 Carriage prevalence at each time point was calculated as the proportion of positive samples
238 over the number of total samples. We also evaluated the proportion of women and children who
239 tested positive for each organism in any sample and at any time point. Due to relatively small
240 sample sizes, the Fisher exact test was used to statistically evaluate associations between
241 carriage outcomes and potential risk factors, and an alpha level of 0.05 was used to determine
242 significance. Data cleaning and analysis were conducted in R (version 4.2.0) [17].

243


244 Results

245

246 In total, 460 samples were collected from 211 women at ANC and/or delivery, and 159 samples
247 were collected from neonates at day 6 after birth (**Figure 1**). Of the 171 women who gave their
248 first sample at an antenatal care appointment, 19 of them also gave a second sample at delivery
249 and 120 of their children provided samples at Day 6 (123 total neonates due to 3 pairs of twins).
250 Many women were not followed up at labor/delivery due to delivering at home (26/152, 17.1%)
251 or at night (106/152, 69.7%) when study data collectors were not present, or other unknown
252 reasons (20/152, 13.2%). Of the 40 women who gave their first sample at delivery, 35 of their
253 children provided samples at Day 6 (36 total neonates due to 1 pair of twins). Overall, 56
254 women who gave samples at ANC and/or labor/delivery did not have neonates who contributed
255 to the study due to ending of the study period (26/56, 46.4%), unavailability of data collector
256 (11/56, 19.6%), missed visits due to social unrest (5/56, 8.9%), family refusal (4/56, 7.1%),
257 migration out of the study area (4/56, 7.1%), stillbirth or early neonatal death (4/56, 7.1%), or
258 sample rejection at the lab (2/56, 3.6%).

259

260 **Figure 1.** Study flow chart.



261

262 Overall, 22.3% of women were positive for ESBL-producing organisms considering any time
263 point or sample type and 0.9% were positive for CRE (**Table 1**). ESBL was more common in
264 rectal swabs compared to vaginal swabs (19.9% vs. 0.6% at ANC and 22.0% vs. 0% at
265 labor/delivery). Carriage prevalence among neonates followed a similar overall pattern, with
266 CRE being much more rare than ESBL. Across all sample types, 24.5% of neonates were
267 positive for ESBL-producing organisms, and 2.5% were positive for CRE. The majority of ESBL-
268 producing isolates were *Escherichia coli* (82/102, 80.3%), followed by *Klebsiella pneumoniae*
269 (13/102, 12.7%) and *Enterobacter cloacae* (7/102, 6.9%). In most cases, one ESBL-producing

270 organism was isolated per specimen; two different organisms were isolated from the same swab
 271 in 15 out of 87 cases (17.2%). The majority of ESBL-producing isolates carried the CTX-M1
 272 gene only (30.7%) or TEM and CTX-M-1 (42.6%) (**Supplementary Table 2**).

273
 274 All 16 CRE-positive isolates harbored more than one resistance gene (**Supplementary Table**
 275 **3**). Among these sequenced isolates, 11 were identified as *E. coli*, 3 as *K. pneumoniae*, and 2
 276 as *E. cloacae*. The majority of isolates (94%) carried at least one beta-lactamase gene, in
 277 different combinations; the most common was CTX-M-15 (68.8%), followed by TEM-1 (43.8%).
 278 Five isolates harbored the carbapenemase OXA-1 gene (31.3%), and one had a point mutation
 279 in the ompK37 locus (6.3%), which can confer resistance to carbapenems and other beta-
 280 lactams through reduced permeability.

281
 282 **Table 1.** Carriage prevalence of ESBL-producing organisms and CRE among mothers and
 283 neonates by time point and sampling site.

Sample type	Time point	Sample size	ESBL % (95% CI)	CRE % (95% CI)
Maternal samples				
Unique women, any sample type	Any	211	22.3 (16.8, 28.5)	0.9 (0.1, 3.4)
Rectal	ANC	171	19.9 (14.2, 26.7)	0 (0, 2.1)
Vaginal	ANC	171	0.6 (0.01, 3.2)	0 (0, 2.1)
Rectal	Labor/delivery	59	22.0 (12.3, 34.7)	3.4 (0.4, 11.7)
Vaginal	Labor/delivery	59	0 (0, 6.1)	0 (0, 6.1)
Neonatal samples				
Unique children, any sample type	Day 6	159	24.5 (18.1, 32.0)	2.5 (0.7, 6.3)
Perirectal	Day 6	73	24.7 (15.3, 36.1)	2.7 (0.3, 9.5)
Stool	Day 6	86	24.4 (15.8, 34.9)	2.3 (0.3, 8.1)

284
 285 There was an association between maternal and neonatal carriage of ESBL-producing
 286 organisms, with 21.1% of women who were never ESBL-positive having children who were
 287 ESBL-positive in the first week of life compared to 38.7% of ESBL-positive women (Fisher exact
 288 test p-value = 0.06). Among the twelve mother-baby pairs that were ESBL-positive, all of the
 289 women carried *E. coli*; 8 of the neonates also had only *E. coli*, 1 neonate had *E. coli* and *E.*
 290 *cloacae*, 1 neonate had *E. coli* and *K. pneumoniae*, 1 neonate had only *E. cloacae*, and 1
 291 neonate had only *K. pneumoniae*. Only one woman whose neonate was also sampled tested
 292 positive for CRE. In addition, 4 neonates tested positive for CRE despite having mothers who
 293 were not positive during pregnancy. Results were similar when focusing only on maternal
 294 samples at labor/delivery (n = 51 mother-baby pairs; ESBL p-value <0.01) (**Supplementary**
 295 **Figure 1**). Among the 4 women whose neonates did not contribute samples due to stillbirth or
 296 early neonatal death, 2 were positive for ESBL and 1 was positive for CRE at ANC or
 297 labor/delivery.

298

299 **Figure 2.** 2x2 tables comparing carriage of ESBL-producing organisms (a) and CRE (b) in
 300 mothers at any point during pregnancy and their neonates.

		Neonate status					Neonate status		
Maternal status (any time point)		ESBL-	ESBL+	Total	Maternal status (any time point)		CRE-	CRE+	Total
ESBL-		101 (78.9%)	27 (21.1%)	128	CRE-		154 (97.5%)	4 (2.5%)	158
ESBL+		19 (61.3%)	12 (38.7%)	31	CRE+		1 (100%)	0 (0%)	1
Total		120	39	159	Total		155	4	159

301 Maternal carriage of ESBL-producing organisms was significantly associated with sample type
 302 (20.4% rectal vs. 0.4% vaginal), woreda of sample collection (42.0% in Kewot vs. 7.7% in
 303 Angolela/Tera), and location of sample collection (38.2% in hospitals vs. 17.9% in health
 304 centers). CRE was also only found on rectal swabs. Although none of the clinical characteristics
 305 reached statistical significance, there is evidence that recent antibiotic use is associated with
 306 carriage of ESBL-producing organisms (27.2% among women who took antibiotics in the last 3
 307 months vs. 20.5% among women who did not) and CRE (4.5% vs. 0.5%). The most common
 308 antibiotics taken were amoxicillin (9/22, 40.9%), cephalexin (3/22, 13.6%), and chloramphenicol
 309 (2/22, 9.1%). Maternal carriage of ESBL-producing organisms was positively associated with
 310 finished household floors and lack of animal cohabitation. Other environmental characteristics
 311 such as household size, toilet type, water source, and livestock ownership were not associated
 312 with carriage of ESBL-producing organisms.
 313
 314

315 **Table 2.** Associations between sample, clinical, and environmental characteristics and carriage
 316 outcomes in pregnant women. Unless otherwise noted, the unit of analysis was the individual-
 317 visit (n = 171 ANC visits + 59 labor/delivery visits = 230); the unit was considered positive if
 318 either the rectal or vaginal swab returned a positive result.

Variable	Sample size	ESBL			CRE		
		Positive n (%)	Negative n (%)	p-value	Positive n (%)	Negative n (%)	p-value
Sample characteristics							
Sample type^a							
Rectal	230	47 (20.4)	183 (79.6)	<0.01	2 (0.9)	228 (99.1)	0.5
Vaginal	230	1 (0.4)	229 (99.6)		0 (0)	230 (100)	
Woreda of sample collection							
Angolela / Tera	142	11 (7.7)	131 (92.3)	<0.01	0 (0)	142 (100)	0.15
Kewot	88	37 (42.0)	51 (58.0)		2 (2.3)	86 (97.7)	
Facility type of sample collection							
Health center	196	35 (17.9)	161 (82.1)	0.011	2 (1.0)	194 (99.0)	1

Hospital	34	13 (38.2)	21 (61.8)		0 (0)	34 (100)	
Clinical characteristics							
Sample collected before membrane rupture (labor/delivery samples only)							
Yes	43	9 (20.9)	34 (79.1)	0.83	0 (0)	43 (100)	0.12
No	14	4 (28.6)	10 (71.4)		2 (14.3)	12 (85.7)	
Missing	2	0 (0)	2 (100)		0 (0)	2 (100)	
Received antibiotics within 3 months before sample collection							
Yes	22	6 (27.2)	16 (72.8)	0.55	1 (4.5)	21 (95.5)	0.21
No	205	42 (20.5)	163 (79.5)		1 (0.5)	204 (99.5)	
Missing	3	0 (0)	3 (100)		0 (0)	3 (100)	
Hospitalized within 3 months before sample collection							
Yes	2	1 (50.0)	1 (50.0)	0.45	0 (0)	2 (100)	1
No	225	47 (20.9)	178 (79.1)		2 (0.9)	223 (99.1)	
Missing	9	0 (0)	3 (100)		0 (0)	3 (100)	
Environmental factors							
Residence type							
Rural	173	38 (22.0)	135 (78.0)	0.57	2 (1.2)	171 (98.8)	1
Urban	57	10 (17.5)	47 (82.5)		0 (0)	57 (100)	
Household size							
4 individuals (median) or fewer	112	30 (26.8)	82 (73.2)	0.11	1 (0.9)	111 (99.1)	1
More than 4 individuals	69	10 (14.5)	59 (85.5)		1 (1.4)	68 (98.6)	
Missing	49	8 (16.3)	41 (83.7)		0 (0)	49 (100)	
Type of toilet at home							
Pit latrine with slab	32	3 (9.4)	29 (90.6)	0.14	0 (0)	32 (100)	1
Pit latrine without slab	74	21 (28.4)	53 (71.6)		1 (1.4)	73 (98.6)	
Other	75	16 (21.3)	59 (78.7)		1 (1.3)	74 (98.7)	
Missing	49	8 (16.3)	41 (83.7)		0 (0)	49 (100)	
Drinking water source at home							
Piped to home or nearby	50	11 (22.0)	39 (78.0)	0.44	1 (2.0)	49 (98.0)	0.71
Public tap	58	16 (27.6)	42 (72.4)		0 (0)	58 (100)	
Well, spring, or surface water	71	13 (18.3)	58 (81.7)		1 (1.4)	70 (98.6)	

Missing	51	8 (15.7)	43 (84.3)		0 (0)	51 (100)	
Flooring material at home							
Natural	121	20 (16.5)	101 (83.5)	0.027	2 (1.7)	119 (98.3)	1
Finished	60	20 (33.3)	40 (66.7)		0 (0)	60 (100)	
Missing	49	8 (16.3)	41 (83.7)		0 (0)	49 (100)	
Own livestock							
Yes	89	17 (19.1)	72 (80.9)	0.44	1 (1.1)	88 (98.9)	1
No	92	23 (25.0)	69 (75.0)		1 (1.1)	91 (98.9)	
Missing	49	8 (16.3)	41 (83.7)		0 (0)	49 (100)	
Domestic animals cohabit with humans							
Yes	42	3 (7.1)	39 (92.9)	0.022	1 (2.4)	41 (97.6)	0.23
No	120	26 (21.7)	94 (78.3)		0 (0)	120 (100)	
Missing	68	19 (27.9)	49 (72.1)		1 (1.5)	67 (98.5)	

^aThe unit of analysis for this variable was each sample.

319
 320
 321 As with the maternal samples, ESBL-producing organisms were more common among
 322 neonates in Kewot (46.6%) compared to Angolela/Tera (11.9%). In addition, early exposure to
 323 antibiotics, either from maternal exposure at labor/delivery or after birth, was associated with
 324 neonatal carriage of ESBL-producing organisms and CRE. Among the 9 neonates who received
 325 antibiotics in the first week of life, 66.7% and 22.2% tested positive for ESBL-producing
 326 organisms and CRE, respectively, compared to 22.7% and 1.4% among neonates who did not
 327 receive antibiotics; in most cases (7/9, 77.8%), ampicillin was administered in combination with
 328 at least one other antibiotic, typically gentamicin (5/7, 71.4%), but ceftriaxone, cefotaxime,
 329 ceftazidime, vancomycin, metronidazole, and cloxacillin were also administered to at least one
 330 neonate each. A much higher proportion of neonates born in the hospital tested positive for
 331 ESBL-producing organisms compared to neonates born in the community (51.5% vs. 13.6%). In
 332 addition, all 4 neonates who tested positive for CRE were born in a health center or hospital.
 333 Both neonates who received care in a health facility in the first week of life also tested positive
 334 for ESBL-producing organisms. None of the environmental characteristics we explored were
 335 associated with neonatal carriage outcomes.

336
 337 **Table 3.** Associations between sample, clinical, and environmental characteristics and carriage
 338 outcomes in neonates.

Variable	Sample size	ESBL			CRE		
		Positive n (%)	Negative n (%)	p-value	Positive n (%)	Negative n (%)	p-value
Sample characteristics							
Sample type							

Perirectal	73	18 (24.7)	55 (75.3)		2 (2.7)	71 (97.3)	
Stool	86	21 (24.4)	65 (75.6)	1	2 (2.3)	84 (97.7)	1
Woreda of sample collection							
Angolela / Tera	101	12 (11.9)	89 (88.1)		2 (2.0)	99 (98.0)	
Kewot	58	27 (46.6)	31 (53.4)	<0.01	2 (3.4)	56 (96.6)	0.62
Location of sample collection							
Community	141	32 (22.7)	109 (77.3)		1 (0.7)	140 (99.3)	
Health center or hospital	1	1 (100)	0 (0)		1 (100)	0 (0)	
Other	1	0 (0)	1 (100)		0 (0)	1 (100)	
Missing	16	6 (37.5)	10 (62.5)	0.16	2 (12.5)	14 (87.5)	<0.01
Clinical characteristics							
Preterm birth							
Yes	19	4 (21.1)	15 (78.9)		1 (5.3)	18 (94.7)	
No	135	33 (24.4)	102 (75.6)		3 (2.2)	132 (97.8)	
Missing	5	2 (40.0)	3 (60.0)	0.70	0 (0)	5 (100)	0.48
Location of birth							
Community	22	3 (13.6)	19 (86.4)		0 (0)	22 (100)	
Health center	98	17 (17.3)	81 (82.7)		1 (1.0)	97 (99.0)	
Hospital	33	17 (51.5)	16 (48.5)		3 (9.1)	30 (90.9)	
Missing	6	2 (33.3)	4 (66.7)	<0.01	0 (0)	6 (100)	0.09
Mother received antibiotics at labor/delivery							
Yes	24	11 (45.8)	13 (54.2)		2 (8.3)	22 (91.7)	
No	110	22 (20.0)	88 (80.0)		2 (1.8)	108 (98.2)	
Missing	25	6 (24.0)	19 (76.0)	0.036	0 (0)	25 (100)	0.15
Received antibiotics after birth							
Yes	9	6 (66.7)	3 (33.3)		2 (22.2)	7 (77.8)	
No	141	32 (22.7)	109 (77.3)		2 (1.4)	139 (98.6)	
Missing	9	1 (11.1)	8 (88.9)	0.011	0 (0)	9 (100)	0.03
Received care in facility after birth							
Yes	2	2 (100)	0 (0)		0 (0)	2 (100)	
No	140	31 (22.1)	109 (77.9)	0.046	2 (1.4)	138 (98.6)	0.12

Unknown	1	0 (0)	1 (100)		0 (0)	1 (100)	
Missing	16	6 (37.5)	10 (62.5)		2 (12.5)	14 (87.5)	
Environmental factors							
Residence type							
Rural	128	34 (26.6)	94 (73.4)		3 (2.3)	125 (97.7)	
Urban	31	5 (16.1)	26 (83.9)	0.26	1 (3.2)	30 (96.8)	0.58
Household size							
4 individuals or fewer	72	20 (27.8)	52 (72.2)		4 (5.6)	68 (94.4)	
More than 4 individuals	55	11 (20.0)	44 (80.0)		0 (0)	55 (100)	
Missing	32	8 (25.0)	24 (75.0)	0.62	0 (0)	32 (100)	0.14
Type of toilet at home							
Pit latrine with slab	22	6 (27.3)	16 (72.7)		1 (4.5)	21 (95.5)	
Pit latrine without slab	52	12 (23.1)	40 (76.9)		0 (0)	52 (100)	
Other	53	13 (24.5)	40 (75.5)		3 (5.7)	50 (94.3)	
Missing	32	8 (25.0)	24 (75.0)	0.99	0 (0)	32 (100)	0.15
Drinking water source at home							
Piped to home or nearby	25	5 (20.0)	20 (80.0)		0 (0)	25 (100)	
Public tap	47	14 (29.8)	33 (70.2)		1 (2.1)	46 (97.9)	
Well, spring, or surface water	53	11 (20.8)	42 (79.2)		3 (5.7)	50 (94.3)	
Missing	34	9 (26.5)	25 (73.5)	0.70	0 (0)	34 (100)	0.48
Flooring material at home							
Natural	88	21 (23.9)	67 (76.1)		3 (3.4)	85 (96.6)	
Finished	39	10 (25.6)	29 (74.4)		1 (2.6)	38 (97.4)	
Missing	32	8 (25.0)	24 (75.0)	0.97	0 (0)	32 (100)	0.81
Own livestock							
Yes	64	12 (18.8)	52 (81.2)		1 (1.6)	63 (98.4)	
No	63	19 (30.2)	44 (69.8)		3 (4.8)	60 (95.2)	
Missing	32	8 (25.0)	24 (75.0)	0.31	0 (0)	32 (100)	0.43
Domestic animals cohabit with humans							
Yes	25	5 (20.0)	20 (80.0)		0 (0)	25 (100)	
No	94	22 (23.4)	72 (76.6)	0.66	2 (2.1)	92 (97.9)	0.62

Missing	40	12 (30.0)	28 (70.0)		2 (5.0)	38 (95.0)	
---------	----	-----------	-----------	--	---------	-----------	--

339

340 One case of neonatal sepsis occurred among the infants in our study. This case occurred prior
341 to the Day 6 visit, which took place in the hospital, and was treated with the standard regimen of
342 ampicillin and gentamicin. This neonate tested positive for both CRE and ESBL at Day 6, but we
343 cannot determine whether these organisms were involved in the infection, arose during
344 treatment, or were acquired later.

345

346 *Carriage prevalence of Group B Streptococcus*

347

348 All samples were also assessed for presence of GBS. Overall, we found that carriage
349 prevalence of GBS was rare in our study population. Only one woman tested positive for GBS at
350 any time point (0.5%, at ANC). Two neonates tested positive (1.3%), though neither of their
351 mothers tested positive. Both positive neonates were born in a health facility.

352

353 **Discussion**

354

355 Among 211 pregnant women and 159 of their neonates in Amhara, Ethiopia, carriage
356 prevalence of ESBL-producing organisms was around 25%, and carriage prevalence of CRE
357 and GBS were less than 3%. Carriage of ESBL-producing organisms was associated with
358 recent exposure to antibiotics and healthcare settings, though these relationships were not
359 statistically significant for the maternal samples. In addition, ESBL-producing organisms were
360 more common in rectal compared to vaginal maternal samples and in Kewot, where the climate
361 is warmer and rainier compared to Angolela/Tera. Maternal carriage of ESBL-producing
362 organisms at ANC or labor/delivery was associated with neonatal carriage in the first week of
363 life.

364

365 There were 27, 4, and 2 newborns who tested positive for ESBL-producing organisms, CRE,
366 and GBS, respectively, but had mothers who did not test positive during pregnancy. In most
367 cases (21 ESBL, 2 CRE, 1 GBS), the women contributed samples at ANC only; it is possible
368 that they acquired the organisms later in pregnancy and would have tested positive at
369 labor/delivery. However, the neonates may also have become colonized through separate
370 pathways. Investigation of such pathways may be important to inform future interventions to
371 prevent neonatal carriage and potential infection with these pathogens. Many of the neonates
372 with either ESBL-producing organisms (10/27, 37%) or CRE (3/4, 75%) were exposed to
373 antibiotics during labor/delivery or after birth, which may have selected for antibiotic-resistant
374 organisms. Many of the neonates were also born in a hospital (11/27 or 41% for ESBL, 3/4 or
375 75% for CRE) or health center (11/27 or 41% for ESBL, 1/4 or 25% for CRE), where they may
376 have been exposed to antibiotic-resistant organisms.

377

378 To our knowledge, this was the first study to measure asymptomatic carriage prevalence of
379 antimicrobial-resistant organisms and GBS in rural Ethiopia. The colonization prevalence
380 estimates in our study were lower than existing reports from Ethiopia, a difference that may be
381 partially attributable to study population. For example, a meta-analysis found that the

382 prevalence of ESBL-producing Gram-negative bacteria across 17 studies in Ethiopia was 48.9%
383 (95% CI: 40.2, 57.75) [19] compared to 20-25% in our study. Nearly all studies in the meta-
384 analysis used clinical samples from patients visiting or staying in a health facility, which may
385 have led to higher prevalence estimates. CRE has not been frequently measured in Ethiopia,
386 but two facility-based studies have reported prevalence estimates of 2.4% (NICU) and 12.12%
387 (inpatients and outpatients <15 years old) for carbapenemase-producing Gram-negative
388 bacteria in clinical samples from children [20,21], compared to our estimate of 2.5% among
389 children in the community. Finally, a recent systematic review of 16 studies in Ethiopia
390 estimated that GBS prevalence in pregnant women was 16% (95% CI: 13, 20) [18] compared to
391 0.5% in our study. However, the majority of studies were conducted in large cities, where
392 prevalence may differ from rural regions.

393
394 Existing studies of colonization in pregnant women and their babies have focused on GBS; a
395 meta-analysis of 31 studies of mothers colonized with GBS estimated that 38.9% (95% CI: 29.6,
396 48.2) of their newborns had surface GBS colonization [22], similar to our estimate of 38.7% for
397 ESBL-producing organisms shared between mothers and children. We also explored clinical
398 and environmental risk factors that were previously shown to be associated with AMR
399 colonization [23], but likely did not have enough power to detect significant associations in some
400 cases. As expected, prior antibiotic use emerged as a risk factor for carriage of ESBL-producing
401 organisms. This association may not have been significant for pregnant women as they could
402 have taken antibiotics up to 3 months prior to sampling, while for neonates, antibiotic exposure
403 occurred within a week prior to sampling. ESBL-producing organisms were more common
404 among both pregnant women and neonates in Kewot woreda, which is warmer, rainier, and at
405 lower altitude than Angolela/Tera. This finding may also reflect differences in healthcare seeking
406 behavior, antibiotic use, and/or infection prevalence between the woredas, though further
407 research is needed to measure these factors. Maternal carriage of ESBL-producing organisms
408 was also associated with household flooring material and cohabitation with domestic animals.
409 Prevalence was higher among women with finished floors compared to natural floors and
410 among households in which animals did not share rooms with humans. These observations run
411 counter to our expectations and may be the result of confounding; for example, women with
412 higher socioeconomic status may be more likely to have finished floors and also more likely to
413 receive care at hospitals and be exposed to antibiotic-resistant organisms.

414
415 Our study has many strengths. We leveraged the well-characterized maternal and child health
416 cohort of the Birhan HDSS in Amhara, Ethiopia. Due to the existing infrastructure, we were able
417 to follow mother-baby pairs longitudinally from ANC to after birth. As data is available on all
418 households and pregnant women and children are followed up frequently as part of the cohort,
419 we had detailed information on clinical, environmental, socioeconomic and demographic factors.
420 Sample processing and validation were conducted by a trained team at NICD in South Africa.
421 PCR and WGS techniques were used to identify antibiotic resistance genes; this type of data is
422 sparse for rural, LMIC settings.

423
424 However, our study was also subject to several limitations. First, we were unable to collect
425 samples for many women at labor/delivery due to time of delivery (e.g., delivering at night when

426 our data collectors were not available to collect samples), or location of delivery. Although
427 carriage at labor/delivery would likely be the most indicative measure of neonatal carriage, the
428 samples collected at late-term antenatal care (after 35 weeks) reflect the typical time period for
429 screening of GBS [24]. Next, due to the small sample size, we were unable to control for
430 confounding through multivariate analyses; however, the associations reported here may
431 contribute to hypotheses for future research. Lastly, we limited our study to neonatal
432 colonization rather than neonatal infection, as assessing this relatively rare outcome
433 prospectively would have required a very large sample size. However, because we are nested
434 within an ongoing surveillance cohort, we were able to observe one case of neonatal sepsis that
435 occurred in our study population.

436

437 **Conclusions**

438

439 In a rural area of Amhara, Ethiopia, maternal and neonatal carriage of ESBL-producing
440 organisms was around 25%, and carriage of CRE and GBS were very rare. Neonates whose
441 mothers tested positive for ESBL-producing organisms at late-term antenatal care or
442 labor/delivery were roughly twice as likely to test positive in the first week after birth. Based on
443 our findings, future carriage studies of CRE and ESBL-producing organisms can focus on rectal
444 swabs, the source of nearly all isolates, over vaginal swabs. In some cases, neonates carried
445 ESBL-producing organisms, CRE, or GBS even though their mothers did not, potentially due to
446 antibiotic use or exposure in health facilities. Increased monitoring of ESBL-producing
447 organisms may be warranted, particularly in healthcare settings and in the Kewot woreda, to
448 understand transmission pathways and inform recommended interventions, such as maternal
449 screening or vaccination for certain organisms. Our study helps to fill a knowledge gap
450 regarding carriage prevalence of key bacterial pathogens among pregnant women and
451 neonates in this region.

452

453 **Acknowledgements**

454

455 We would like to extend our gratitude to the families who participated in this study and made
456 this work possible. We appreciate the HaSET data collectors and field team for their tireless
457 efforts to successfully implement this study. We are grateful for the support of the HaSET
458 community advisory board. We would also like to thank Anne Redmond Sites and Clara Pons
459 Durans for their helpful comments on the manuscript. Finally, we would like to thank the Whole
460 Genome Sequencing facility at NICD for helping with analysis of data and Ruth Mogokotleng for
461 interpretation.

462

463 **Author contributions (based on CRediT Taxonomy)**

464

465 *Conceptualization:* C.T.W., D.B., G.C.

466 *Data curation:* G.A., C.T.W., O.P., A.G., M.S.

467 *Formal analysis:* G.A., C.T.W.

468 *Funding acquisition:* G.C.

469 *Investigation:* G.A., C.T.W., O.P., A.G., M.S., G.C.

470 *Methodology:* G.A., C.T.W., O.P., B.M.H., M.S., D.B., G.C.

471 *Project administration:* G.A., O.P., A.G., M.S., A.F., G.C.

472 *Resources:* G.A., O.P., A.G., M.S., A.F., G.C.

473 *Software:* C.T.W.

474 *Supervision:* O.P., D.B., L.T., G.C.

475 *Validation:* G.A., C.T.W., O.P., M.S.

476 *Visualization:* C.T.W.

477 *Writing – original draft preparation:* G.A., C.T.W., O.P.

478 *Writing – review & editing:* All

479

480 **Data availability**

481

482 De-identified data will be made publicly available upon publication of the manuscript.

483

484 **Conflict of Interest statement**

485

486 The authors have no conflicts of interest to report.

487

488 **Funding**

489

490 This work was supported by the Bill & Melinda Gates Foundation [INV-010382 to G.C.].

491 **References**

- 492
- 493 1. Lawn JE, Blencowe H, Oza S, You D, Lee AC, Waiswa P, et al. Every Newborn: progress,
494 priorities, and potential beyond survival. *The Lancet*. 2014 Jul;384(9938):189–205.
 - 495 2. World Health Organization. Newborn Mortality [Internet]. 2022 [cited 2022 Nov 11].
496 Available from: [https://www.who.int/news-room/fact-sheets/detail/levels-and-trends-in-](https://www.who.int/news-room/fact-sheets/detail/levels-and-trends-in-child-mortality-report-2021)
497 [child-mortality-report-2021](https://www.who.int/news-room/fact-sheets/detail/levels-and-trends-in-child-mortality-report-2021)
 - 498 3. Downie L, Armiento R, Subhi R, Kelly J, Clifford V, Duke T. Community-acquired neonatal
499 and infant sepsis in developing countries: efficacy of WHO’s currently recommended
500 antibiotics--systematic review and meta-analysis. *Arch Dis Child*. 2013 Feb 1;98(2):146–
501 54.
 - 502 4. Chan GJ, Lee AC, Baqui AH, Tan J, Black RE. Risk of Early-Onset Neonatal Infection with
503 Maternal Infection or Colonization: A Global Systematic Review and Meta-Analysis. *PLOS*
504 *Med*. 2013 Aug 20;10(8):e1001502.
 - 505 5. Schrag SJ, Phil D, Zywicki S, Harrison LH, Cieslak PR. Group B Streptococcal Disease in
506 the Era of Intrapartum Antibiotic Prophylaxis. *N Engl J Med*. 2000;6.
 - 507 6. Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal
508 group B streptococcal disease: Experience in the United States and implications for a
509 potential group B streptococcal vaccine. *Vaccine*. 2013 Aug 28;31:D20–6.
 - 510 7. Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: When? Where? Why? *The*
511 *Lancet*. 2005 Mar 5;365(9462):891–900.
 - 512 8. Bekele D, Hunegnaw BM, Bekele C, Van Wickle K, Tadesse F, Goddard FGB, et al.
513 Cohort Profile: The Birhan Health and Demographic Surveillance System. *Int J Epidemiol*.
514 2022 Apr 1;51(2):e39–45.
 - 515 9. Chan GJ, Goddard FGB, Hunegnaw BM, Mohammed Y, Hunegnaw M, Haneuse S, et al.
516 Estimates of Stillbirths, Neonatal Mortality, and Medically Vulnerable Live Births in Amhara,
517 Ethiopia. *JAMA Netw Open*. 2022 Jun 24;5(6):e2218534.
 - 518 10. Chan GJ, Hunegnaw BM, Van Wickle K, Mohammed Y, Hunegnaw M, Bekele C, et al.
519 Birhan maternal and child health cohort: a study protocol. *BMJ Open*. 2021
520 Sep;11(9):e049692.
 - 521 11. CLSI M100- \square : Performance Standards for Antimicrobial Susceptibility Testing. 2022 Feb.
522 Report No.: 32nd edition.
 - 523 12. Birkett CI, Ludlam HA, Woodford N, Brown DFJ, Brown NM, Roberts MTM, et al. Real-time
524 TaqMan PCR for rapid detection and typing of genes encoding CTX-M extended-spectrum
525 beta-lactamases. *J Med Microbiol*. 2007 Jan;56(Pt 1):52–5.
 - 526 13. Harris SR. SKA: Split Kmer Analysis Toolkit for Bacterial Genomic Epidemiology [Internet].
527 Genomics; 2018 Oct [cited 2023 Mar 5]. Available from:
528 <http://biorxiv.org/lookup/doi/10.1101/453142>
 - 529 14. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, et al. ResFinder 4.0 for
530 predictions of phenotypes from genotypes. *J Antimicrob Chemother*. 2020 Dec
531 1;75(12):3491–500.
 - 532 15. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, et al. Validating the
533 AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance
534 Genotype-Phenotype Correlations in a Collection of Isolates. *Antimicrob Agents*
535 *Chemother*. 2019 Nov;63(11):e00483-19.
 - 536 16. Joensen KG, Scheutz F, Lund O, Hasman H, Kaas RS, Nielsen EM, et al. Real-time
537 whole-genome sequencing for routine typing, surveillance, and outbreak detection of
538 verotoxigenic *Escherichia coli*. *J Clin Microbiol*. 2014 May;52(5):1501–10.
 - 539 17. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna,
540 Austria: R Foundation for Statistical Computing; 2022. Available from: <https://www.R->

- 541 project.org/
542 18. Lemma D, Huluka TK, Chelkeba L. Prevalence and antimicrobial susceptibility of group B
543 streptococci among pregnant women in Ethiopia: A systemic review and meta-analysis
544 study. *SAGE Open Med.* 2022 Jan 1;10:20503121221081336.
545 19. Abayneh M, Worku T. Prevalence of multidrug-resistant and extended-spectrum beta-
546 lactamase (ESBL)-producing gram-negative bacilli: A meta-analysis report in Ethiopia.
547 *Drug Target Insights.* 2020 Oct 5;14:16–25.
548 20. Zakir A, Dadi BR, Aklilu A, Oumer Y. Investigation of Extended-Spectrum β -Lactamase
549 and Carbapenemase Producing Gram-Negative Bacilli in. *Infect Drug Resist.* :12.
550 21. Legese MH, Weldearegay GM, Asrat D. Extended-spectrum beta-lactamase- and
551 carbapenemase-producing Enterobacteriaceae among Ethiopian children. *Infect Drug*
552 *Resist.* 2017 Jan 25;10:27–34.
553 22. Chan GJ, Lee AC, Baqui AH, Tan J, Black RE. Prevalence of early-onset neonatal
554 infection among newborns of mothers with bacterial infection or colonization: a systematic
555 review and meta-analysis. *BMC Infect Dis.* 2015 Mar 7;15(1):118.
556 23. Chatterjee A, Modarai M, Naylor NR, Boyd SE, Atun R, Barlow J, et al. Quantifying drivers
557 of antibiotic resistance in humans: a systematic review. *Lancet Infect Dis.* 2018 Dec
558 1;18(12):e368–78.
559 24. The American College of Obstetricians and Gynecologists (ACOG). Group B Strep and
560 Pregnancy [Internet]. 2021 [cited 2022 Nov 12]. Available from:
561 <https://www.acog.org/en/womens-health/faqs/group-b-strep-and-pregnancy>